Overview

Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis (MS)

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To provide efficacy and safety data of two doses (0.5 mg and 1.25 mg) of FTY720 in Japanese patients with relapsing multiple sclerosis (MS)
Phase:
Phase 2
Details
Lead Sponsor:
Novartis
Collaborator:
Mitsubishi Tanabe Pharma Corporation
Treatments:
Fingolimod Hydrochloride